OR WAIT null SECS
February 21, 2026
Article
February 19, 2026
Positive results from a follow-up preclinical study of Thykamine show dose-dependent effects on key pathological hallmarks of MASH.
Interim data from the investigator-initiated trial showed treatment with a single dose of YOLT-202 led to rapid, dose-dependent increases in AAT levels to normal range.
February 18, 2026
Video
Anouti outlines why early bilirubin testing and emerging serum markers are key to improving prognosis in biliary atresia.
February 13, 2026
Younossi emphasizes the need for NIT-based risk stratification for MASLD, citing his research supporting their widespread adoption across clinical settings.
February 12, 2026
Younossi explains the growing interest in NITs for MASLD and reviews his research on their performance in age, diabetes, and obesity subgroups.
February 11, 2026
Choi explains longstanding hesitancy around statin use in chronic liver disease, particularly cholestatic diseases like PBC, and how his research challenges these sentiments.
February 10, 2026
Choi describes existing evidence on statin use in patients with liver disease and reviews his new research about their potential utility in PBC.
Patients with severe hypertriglyceridemia and MASLD saw reductions in fasting triglyceride and improvements in remnant cholesterol and hepatic fat.
In this segment of a Liver Lineup episode, experts discuss where the new US Dietary Guidelines miss the mark for alcohol recommendations.
